This study will compare DS 8201a to standard treatment.
Participants must have HER2 breast cancer that has been treated before.
The study is designed to compare DS 8201a versus standard of care (investigator's choice) in subjects with unresectable and/or metastatic breast cancer previously treated with T-DM1.
|Treatment||Capecitabine, Trastuzumab, Lapatinib, Trastuzumab deruxtecan|
|Clinical Study Identifier||NCT03523585|
|Sponsor||Daiichi Sankyo, Inc.|
|Last Modified on||13 January 2021|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.